Short Integrative And Neurocognitive Therapy For Young Adults With Borderline Personality Disorder

Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE NĪMES · Jun 12, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new therapy called SINTYA for young adults aged 16 to 25 who have borderline personality disorder (BPD), a mental health condition that can cause intense emotions, impulsive actions, and self-destructive behaviors. The researchers believe that SINTYA, which includes one group session and one individual session each week for 10 weeks, can help reduce these challenging symptoms and improve overall functioning in daily life.

To be eligible for this study, participants must have a diagnosis of BPD and significant symptoms, be able to read and write in French, and understand what the study involves. It is important for participants to be willing to cooperate and have parental consent if they are minors. Those with certain other mental health conditions, neurological issues, or who have participated in similar therapies recently will not be able to take part. If someone joins the study, they can expect regular sessions aimed at helping them manage their symptoms better over the course of the trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of BPD according to DSM-5 criteria and BPQ-80 scale.
• • High BPD severity level: ZAN-BPD (score ≥ 18/36).
• • Understand, write and read French.
• • Be able to understand the nature, purpose and methodology of the study and agree to cooperate during evaluations.
• • Have signed the informed consent.
• • For minor patients, have signed the parental consent by at least one holder of parental authority.
• Exclusion Criteria:
• • Refusal to participate.
• • Existence of a neurological pathology or cerebral sequelae of organic origin which could affect neurocognitive performance.
• • Intelligence quotient \< 70.
• • Lifetime diagnosis of schizoaffective disorder or schizophrenia (MINI-7).
• • Previous or current participation in specific psychotherapy for BPD.
• • Subject deprived of liberty (by judicial or administrative decision) and/or protected by law.
• • Inclusion in another study including psychotherapy for the duration of the study.
• • Inclusion in a drug RIPH1 study or in a REC study (European regulation of clinical trials) for the entire duration of the study.
• • Subject in period of exclusion from another research protocol.